Mechanisms of Action of Carbapenem Resistance.
antibiotic resistance
carbapenem antimicrobials
infections
β-lactams antibiotics
Journal
Antibiotics (Basel, Switzerland)
ISSN: 2079-6382
Titre abrégé: Antibiotics (Basel)
Pays: Switzerland
ID NLM: 101637404
Informations de publication
Date de publication:
21 Mar 2022
21 Mar 2022
Historique:
received:
09
02
2022
revised:
10
03
2022
accepted:
17
03
2022
entrez:
25
3
2022
pubmed:
26
3
2022
medline:
26
3
2022
Statut:
epublish
Résumé
Carbapenem antibiotics are the most effective antimicrobials for the treatment of infections caused by the most resistant bacteria. They belong to the category of β-lactams that include the penicillins, cephalosporins, monobactams and carbapenems. This class of antimicrobials has a broader spectrum of activity than most other beta-lactams antibiotics and are the most effective against Gram-positive and Gram-negative bacteria. All β-lactams antibiotics have a similar molecular structure: the carbapenems together with the β-lactams. This combination gives an extraordinary stability to the molecule against the enzymes inactivating the β-lactams. They are safe to use and therefore widespread use in many countries has given rise to carbapenem resistance which is a major global public health problem. The carbapenem resistance in some species is intrinsic and consists of the capacity to resist the action of antibiotics with several mechanisms: for the absence of a specific target, or an intrinsic difference in the composition of cytoplasmatic membrane or the inability to cross the outer membrane. In addition to intrinsic resistance, bacteria can develop resistance to antibiotics with several mechanisms that can be gathered in three main groups. The first group includes antibiotics with poor penetration into the outer membrane of bacterium or antibiotic efflux. The second includes bacteria that modify the target of the antibiotics through genetic mutations or post-translational modification of the target. The third includes bacteria that act with enzyme-catalyzed modification and this is due to the production of beta-lactamases, that are able to inactivate carbapenems and so called carbapenemases. In this review, we focus on the mode of action of carbapenem and the mechanisms of carbapenem resistance.
Identifiants
pubmed: 35326884
pii: antibiotics11030421
doi: 10.3390/antibiotics11030421
pmc: PMC8944602
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
J Antimicrob Chemother. 2013 Aug;68(8):1697-706
pubmed: 23543608
Drugs. 2007;67(7):1027-52
pubmed: 17488146
Cold Spring Harb Perspect Biol. 2010 May;2(5):a000414
pubmed: 20452953
Emerg Infect Dis. 2011 Oct;17(10):1791-8
pubmed: 22000347
Am J Med. 1985 Jun 7;78(6A):3-21
pubmed: 3859213
Clin Microbiol Rev. 2007 Jul;20(3):440-58, table of contents
pubmed: 17630334
Ther Adv Infect Dis. 2016 Feb;3(1):15-21
pubmed: 26862399
JAMA. 2008 Dec 24;300(24):2911-3
pubmed: 19109119
Expert Rev Anti Infect Ther. 2013 Jun;11(6):543-5
pubmed: 23750724
Emerg Infect Dis. 2011 Jan;17(1):143-4
pubmed: 21192883
Antimicrob Agents Chemother. 2011 Nov;55(11):4943-60
pubmed: 21859938
Life (Basel). 2021 May 24;11(6):
pubmed: 34073847
Life (Basel). 2021 Jun 23;11(7):
pubmed: 34201519
Antimicrob Agents Chemother. 2010 Jan;54(1):565-9
pubmed: 19884379
Chembiochem. 2009 Mar 2;10(4):617-24
pubmed: 19173317
Infect Drug Resist. 2018 Apr 11;11:523-530
pubmed: 29695921
Clin Infect Dis. 1997 Feb;24 Suppl 2:S184-90
pubmed: 9126692
Infect Drug Resist. 2018 Oct 10;11:1645-1658
pubmed: 30349322
Front Microbiol. 2021 Feb 16;11:610109
pubmed: 33664711
Antimicrob Agents Chemother. 2010 Oct;54(10):4493-6
pubmed: 20696875
J Biol Chem. 2011 Jul 15;286(28):25265-73
pubmed: 21597116
J Antimicrob Chemother. 2011 Feb;66(2):307-12
pubmed: 21131324
Antimicrob Agents Chemother. 2004 Dec;48(12):4793-9
pubmed: 15561858
Infect Drug Resist. 2020 Feb 12;13:423-434
pubmed: 32104014
Clin Microbiol Rev. 2018 Aug 1;31(4):
pubmed: 30068738
Antimicrob Agents Chemother. 2001 Apr;45(4):1151-61
pubmed: 11257029
Front Microbiol. 2020 Apr 17;11:573
pubmed: 32373082
Clin Microbiol Rev. 2012 Oct;25(4):682-707
pubmed: 23034326
Science. 2012 Aug 31;337(6098):1107-11
pubmed: 22936781
Proteins. 2013 Feb;81(2):291-9
pubmed: 23011778
J Antimicrob Chemother. 2013 Jun;68(6):1319-26
pubmed: 23478794
Microb Drug Resist. 2006 Winter;12(4):223-30
pubmed: 17227206
Antimicrob Agents Chemother. 2019 Feb 26;63(3):
pubmed: 30642939
Emerg Infect Dis. 2010 Sep;16(9):1349-56
pubmed: 20735917
J Antimicrob Chemother. 2008 Dec;62(6):1261-4
pubmed: 18812425
Int J Antimicrob Agents. 2015 Jun;45(6):568-85
pubmed: 25857949
Life (Basel). 2021 Jun 03;11(6):
pubmed: 34204961
J Antimicrob Chemother. 2007 Sep;60(3):470-82
pubmed: 17595289
New Microbes New Infect. 2019 Apr 10;30:100549
pubmed: 31193498
Antimicrob Agents Chemother. 2012 Mar;56(3):1273-80
pubmed: 22155830
Clin Microbiol Infect. 2008 Dec;14(12):1102-11
pubmed: 19076841